FDMT Financials

Income Statement
MetricQ2 2026Q1 2026Q4 2025Q3 2025Q2 2025
Revenue
3.8M
+24.1%
3.0M
-96.4%
85.1M
+94444.4%
90.0K
+500.0%
15.0K
Cost of Revenue
0
0
0
0
0
Gross Profit
3.8M
+24.1%
3.0M
-96.4%
85.1M
+94444.4%
90.0K
+500.0%
15.0K
Operating Expenses
80.8M
+5.4%
76.7M
+8.9%
70.4M
+14.9%
61.3M
+3.0%
59.5M
R&D
68.3M
+5.1%
65.0M
+12.8%
57.6M
+16.5%
49.4M
+3.1%
48.0M
SG&A
12.5M
+7.2%
11.7M
-8.5%
12.8M
+7.9%
11.8M
+2.8%
11.5M
Operating Income
-77025000
-4.6%
-73620000
-600.3%
14.7M
+124.1%
-61185000
-2.9%
-59456000
EBITDA
-75745000
-4.7%
-72351000
-554.2%
15.9M
+126.6%
-59924000
-2.8%
-58290000
Net Income
-72936000
-6.1%
-68760000
-454.5%
19.4M
+134.1%
-56876000
-4.1%
-54658000
EPS (Basic)
$-1.04
-3.0%
$-1.01
-436.7%
$0.30
+129.7%
$-1.01
-3.1%
$-0.98
EPS (Diluted)
$-1.04
-3.0%
$-1.01
-436.7%
$0.30
+129.7%
$-1.01
-3.1%
$-0.98
Shares (Diluted)
70.3M
+3.2%
68.1M
+6.5%
63.9M
+13.9%
56.1M
+0.4%
55.9M
4D Molecular Therapeutics (FDMT) โ€” Financials